Αποτελέσματα Αναζήτησης
TYSABRI ® (natalizumab) is available only through the TOUCH Prescribing Program TYSABRI Outreach: Unified Commitment to Health. TOUCH On-Line is a web-based tool designed to assist TOUCH Prescribing Program participants in fulfilling their TOUCH Prescribing Program Requirements.
- Touch On-Line
TOUCH On-Line is a web-based tool designed to assist TOUCH...
- How to Enroll
TOUCH On-Line. How do I enroll in the TOUCH Prescribing...
- Touch On-Line
TOUCH On-Line is a web-based tool designed to: Provide real-time access to data for patients taking TYSABRI. Maintain compliance with the TOUCH Prescribing Program. Reduce administrative burden/paperwork for prescribers and infusion sites. Streamline communication to/from prescribers and infusion sites.
This page must be submitted on-line (www.touchprogram.com) OR faxed to Biogen (1-800-840-1278) within 1 day of the patient’s visit and a copy retained in the patient’s record whether the patient has been infused or not.
TOUCH On-Line. How do I enroll in the TOUCH Prescribing Program? Prescribers, infusion sites, certified pharmacies associated with infusion sites and patients must all enroll in the TOUCH Prescribing Program in order to prescribe, infuse, dispense or receive TYSABRI. Infusion Sites. Certified Pharmacies.
Το Tysabri χρησιμοποιείται στη θεραπεία της πολλαπλής σκλήρυνσης (ΠΣ). Περιέχει τη δραστική ουσία natalizumab. Αυτό αναφέρεται ως μονοκλωνικό αντίσωμα. Η ΠΣ προκαλεί φλεγμονή στον εγκέφαλο, που προκαλεί βλάβη στα νευρικά κύτταρα. Αυτή η φλεγμονή εμφανίζεται όταν τα λευκά αιμοσφαίρια εισέρχονται στον εγκέφαλο και στον νωτιαίο μυελό.
• TOUCH On-Line is a web-based tool designed to: – Provide real-time access to TYSABRI patient data – Maintain compliance with the TOUCH Prescribing Program – Reduce administrative burden/paperwork for prescribers and infusion sites • TOUCH On-Line is accessed with secure username and password How the program works
TYSABRI is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML).
